Zingo

What is Zingo?

• Zingo (lidocaine hydrochloride monohydrate) indicated for use on intact skin to provide topical local analgesia.

Lidocaine

Error creating thumbnail:

Lidocaine hci

Error creating thumbnail:

Lidocaine spin

What are the uses of this medicine?

• Zingo (lidocaine hydrochloride monohydrate) indicated for use on intact skin to provide topical local analgesia prior to venipuncture or peripheral intravenous cannulation, in children 3–18 years of age.
• ZINGO is indicated for use on intact skin to provide topical local analgesia prior to venipuncture in adults.

How does this medicine work?

• ZINGO delivers lidocaine hydrochloride monohydrate into the dermis.
• Lidocaine is an amide-type local anesthetic agent that blocks sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.

Who Should Not Use this medicine ?

This medicine cannot be used in patients with:

• a known history of sensitivity to local anesthetics of the amide type.

What drug interactions can this medicine cause?

• Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs:
• Nitrates/Nitrites (nitric oxide, nitroglycerin, nitroprusside, nitrous oxide)
• Local anesthetic (sarticaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine)
• Antineoplastic agents (cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase)
• Antibiotics (dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides)
• Antimalarials (chloroquine, primaquine)
• Anticonvulsants (phenobarbital, phenytoin, sodium valproate)
• Other drugs([[acetaminophen], metoclopramide, quinine, sulfasalazine)

Is this medicine FDA approved?

• Lidocaine was approved for use as a local anesthetic in the 1948.

How should this medicine be used?

Recommended dosage:

• Apply one ZINGO (0.5 mg lidocaine hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion.
• Perform the procedure within 10 minutes after ZINGO administration.
• Multiple administrations of ZINGO at the same location are not recommended.

Administration:

• Use ZINGO only on intact skin.
• Examine the treatment site to ensure that the skin is intact.
• Clean the site, according to standard practice.
• Grip ZINGO and place on the application site, with one hand.
• Seal the purple ZINGO outlet against the patient’s skin.
• Hold the device perpendicular to the skin, making sure that your thumb can reach the green start button.
• Avoid gaps between the skin and the ZINGO outlet.
• Apply adequate downward pressure to release the safety interlock, while maintaining the seal between ZINGO and the skin.
• ZINGO is ready for administration when the green start button has moved into the upward position.
• Administer the dose by pressing the green start button.
• Remove ZINGO from the application site and dispose.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form:

• As a sterile, single-use, powder intradermal injection system containing 0.5 mg lidocaine hydrochloride monohydrate.
• ZINGO utilizes a helium-powered delivery system.

This medicine is available in fallowing brand namesː

• ZINGO

What side effects can this medication cause?

The most common side effects of this medicine include:

• erythema
• petechiae
• edema
• pruritus

What special precautions should I follow?

• Cases of methemoglobinemia have been reported in association with local anesthetic use. Discontinue ZINGO and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
• Use on intact skin only.
• Avoid contact with the eye.
• Do not use if device is dropped or the pouch is damaged or torn.
• Patients with bleeding tendencies or platelet disorders could have a higher risk of superficial dermal bleeding.

What to do in case of emergency/overdose?

Symptoms of overdosage may include:

• seizures
• respiratory arrest
• coma
• decreases in cardiac output
• total peripheral resistance and mean arterial pressure
• ventricular arrhythmias
• cardiac arrest

Management of overdosage:

• The management of overdosage includes close monitoring, supportive care, and symptomatic treatment.
• Dialysis is of negligible value in the treatment of acute overdosage of lidocaine.

Can this medicine be used in pregnancy?

• There are, however, no adequate and well-controlled studies in pregnant women.
• Because animal reproduction studies are not always predictive of human response, ZINGO should be used during pregnancy only if clearly needed.
• Pregnancy Category B.

Can this medicine be used in children?

• Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

What are the active and inactive ingredients in this medicine?

Active ingredients:

• LIDOCAINE HYDROCHLORIDE

Inactive ingredients:

• none

Who manufactures and distributes this medicine?

Manufactured by: Powder Pharmaceuticals, Inc. Hong Kong, China

• ZINGO® is a trademark of Powder Pharmaceuticals, Incorporated.

Distributed by: 7T Pharma LLC Las Vegas, NV , USA

What should I know about storage and disposal of this medication?

• Cartons are stored at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F).

• Dailymed label info on Zingo
• FDA Zingo

Zingo Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.

List of antiarrhythmic agents:

• Amiodarone
• Disopyramide
• Dofetilide
• Dronedarone
• Flecainide
• Ivabradine
• Mexiletine
• Procainamide
• Propafenone
• Quinidine